Basilea Pharmaceutica AG
Develops & commercializes anti-infectives for severe bacterial & fungal infections.
BSLN | SW
Overview
Corporate Details
- ISIN(s):
- CH0011432447 (+1 more)
- LEI:
- 391200TTZP8EIPSJ5J20
- Country:
- Switzerland
- Address:
- Henric Petri-Strasse 35, 4051 Basel
- Website:
- https://www.basilea.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Basilea Pharmaceutica AG is a commercial-stage biopharmaceutical company specializing in the discovery, development, and commercialization of innovative medicines for severe bacterial and fungal infections. The company's key marketed products are the antifungal Cresemba (isavuconazole) and the antibiotic Zevtera (ceftobiprole). Basilea manages the full drug development lifecycle, from research through clinical trials to market launch, aiming to establish its products as global brands. Founded in 2000 as a spin-off from F. Hoffmann-La Roche, the company leverages its expertise to address critical medical needs in the anti-infectives field.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-11-04 01:00 |
Earnings Release
Strong Cresemba® (isavuconazole) sales performance in Europe triggers USD 30 mi…
|
English | 5.9 KB | ||
| 2025-11-04 01:00 |
Earnings Release
Starke Verkaufszahlen für Cresemba® (Isavuconazol) in Europa lösen USD 30 Mio. …
|
German | 6.9 KB | ||
| 2025-09-25 02:00 |
Capital/Financing Update
Basilea awarded BARDA contract for the development of novel oral phase 3-ready …
|
English | 8.7 KB | ||
| 2025-09-25 02:00 |
Capital/Financing Update
Basilea schliesst eine Fördervereinbarung mit BARDA für die Entwicklung des Pha…
|
German | 10.0 KB | ||
| 2025-09-16 02:00 |
Regulatory News Service
Basilea receives USD 25 million funding under BARDA agreement to continue to ad…
|
English | 11.0 KB | ||
| 2025-09-16 02:00 |
Regulatory News Service
Basilea erhält im Rahmen ihrer BARDA-Vereinbarung USD 25 Mio. für die weitere E…
|
German | 12.7 KB | ||
| 2025-08-19 02:00 |
Earnings Release
Basilea on track with strong 2025 half-year results
|
English | 19.5 KB | ||
| 2025-08-19 02:00 |
Earnings Release
Basilea mit starkem Halbjahresergebnis 2025 auf Kurs
|
German | 21.4 KB | ||
| 2025-08-14 02:00 |
M&A Activity
Basilea announces in-licensing of a novel clinical phase 3-ready oral antibiotic
|
English | 11.4 KB | ||
| 2025-08-14 02:00 |
M&A Activity
Basilea gibt Einlizenzierung eines neuartigen oralen Antibiotikums bekannt, das…
|
German | 12.9 KB | ||
| 2025-07-08 02:00 |
Regulatory News Service
Basilea receives USD 39 million funding under BARDA agreement to continue to ad…
|
English | 11.2 KB | ||
| 2025-07-08 02:00 |
Regulatory News Service
Basilea erhält im Rahmen ihrer BARDA-Vereinbarung USD 39 Mio. für die weitere E…
|
German | 13.0 KB | ||
| 2025-02-18 01:00 |
Earnings Release
Basilea reports strong 2024 full-year results with significant increase in reve…
|
English | 19.9 KB | ||
| 2025-02-18 01:00 |
Earnings Release
Basilea meldet für das Gesamtjahr 2024 ein starkes Ergebnis mit deutlichem Anst…
|
German | 23.1 KB | ||
| 2024-12-23 01:00 |
Regulatory News Service
Basilea is awarded additional CARB-X funding to develop new drug candidate from…
|
English | 7.8 KB |
Automate Your Workflow. Get a real-time feed of all Basilea Pharmaceutica AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Basilea Pharmaceutica AG
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Basilea Pharmaceutica AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-05-21 | N/A | Executive member | Sell | None | 27,000.00 CHF |
| 2025-04-30 | N/A | Executive member | Sell | None | 17,600.00 CHF |
| 2025-04-23 | N/A | Executive member | Sell | None | 57,396.20 CHF |
| 2025-04-23 | N/A | Non-Executive member | Sell | None | 30,331.00 CHF |
| 2025-04-17 | N/A | Executive member | Sell | None | 173,479.91 CHF |
| 2025-04-17 | N/A | Executive member | Sell | None | 118,568.67 CHF |
| 2025-04-17 | N/A | Executive member | Sell | None | 41,255.63 CHF |
| 2024-10-28 | N/A | Executive member | Sell | None | 22,500.00 CHF |
| 2024-04-25 | N/A | Executive member | Sell | None | 79,966.26 CHF |
| 2024-04-24 | N/A | Executive member | Sell | None | 23,128.70 CHF |
Peer Companies
